220 related articles for article (PubMed ID: 32363604)
1. Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta-analysis.
Malagón T; Volesky KD; Bouten S; Laprise C; El-Zein M; Franco EL
Int J Cancer; 2020 Nov; 147(10):2695-2707. PubMed ID: 32363604
[TBL] [Abstract][Full Text] [Related]
2. The role of human papillomavirus genotyping for detecting high-grade intraepithelial neoplasia or cancer in HPV-positive women with normal cytology: a study from a hospital in northeastern China.
Zhang J; Zhang D; Yang Z; Wang X; Wang D
BMC Cancer; 2020 May; 20(1):443. PubMed ID: 32429919
[TBL] [Abstract][Full Text] [Related]
3. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.
Kjær SK; Frederiksen K; Munk C; Iftner T
J Natl Cancer Inst; 2010 Oct; 102(19):1478-88. PubMed ID: 20841605
[TBL] [Abstract][Full Text] [Related]
4. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.
Khan MJ; Castle PE; Lorincz AT; Wacholder S; Sherman M; Scott DR; Rush BB; Glass AG; Schiffman M
J Natl Cancer Inst; 2005 Jul; 97(14):1072-9. PubMed ID: 16030305
[TBL] [Abstract][Full Text] [Related]
5. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities.
Castle PE; Solomon D; Schiffman M; Wheeler CM
J Natl Cancer Inst; 2005 Jul; 97(14):1066-71. PubMed ID: 16030304
[TBL] [Abstract][Full Text] [Related]
7. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
8. Incidence risk of cervical intraepithelial neoplasia 3 or more severe lesions is a function of human papillomavirus genotypes and severity of cytological and histological abnormalities in adult Japanese women.
Hosaka M; Fujita H; Hanley SJ; Sasaki T; Shirakawa Y; Abiko M; Kudo M; Kaneuchi M; Watari H; Kikuchi K; Sakuragi N
Int J Cancer; 2013 Jan; 132(2):327-34. PubMed ID: 22729477
[TBL] [Abstract][Full Text] [Related]
9. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.
Safaeian M; Solomon D; Wacholder S; Schiffman M; Castle P
Obstet Gynecol; 2007 Jun; 109(6):1325-31. PubMed ID: 17540804
[TBL] [Abstract][Full Text] [Related]
10. Five-Year Cervical (Pre)Cancer Risk of Women Screened by HPV and Cytology Testing.
Uijterwaal MH; Polman NJ; Van Kemenade FJ; Van Den Haselkamp S; Witte BI; Rijkaart D; Berkhof J; Snijders PJ; Meijer CJ
Cancer Prev Res (Phila); 2015 Jun; 8(6):502-8. PubMed ID: 25776933
[TBL] [Abstract][Full Text] [Related]
11. Risk of cervical precancer and cancer among HIV-infected women with normal cervical cytology and no evidence of oncogenic HPV infection.
Keller MJ; Burk RD; Xie X; Anastos K; Massad LS; Minkoff H; Xue X; D'Souza G; Watts DH; Levine AM; Castle PE; Colie C; Palefsky JM; Strickler HD
JAMA; 2012 Jul; 308(4):362-9. PubMed ID: 22820789
[TBL] [Abstract][Full Text] [Related]
12. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.
Clarke MA; Cheung LC; Castle PE; Schiffman M; Tokugawa D; Poitras N; Lorey T; Kinney W; Wentzensen N
JAMA Oncol; 2019 Feb; 5(2):181-186. PubMed ID: 30325982
[TBL] [Abstract][Full Text] [Related]
13. Long-term cervical precancer outcomes after a negative DNA- or RNA-based human papillomavirus test result.
Strang THR; Gottschlich A; Cook DA; Smith LW; Gondara L; Franco EL; van Niekerk DJ; Ogilvie GS; Krajden M
Am J Obstet Gynecol; 2021 Nov; 225(5):511.e1-511.e7. PubMed ID: 34081897
[TBL] [Abstract][Full Text] [Related]
14. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
[TBL] [Abstract][Full Text] [Related]
15. Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, ≥25 years of age, with NILM cytology.
Stoler MH; Wright TC; Parvu V; Yanson K; Cooper CK; Andrews J
Gynecol Oncol; 2019 Apr; 153(1):26-33. PubMed ID: 30638767
[TBL] [Abstract][Full Text] [Related]
16. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
17. Long-term HPV type-specific risks of high-grade cervical intraepithelial lesions: a 14-year follow-up of a randomized primary HPV screening trial.
Smelov V; Elfström KM; Johansson AL; Eklund C; Naucler P; Arnheim-Dahlström L; Dillner J
Int J Cancer; 2015 Mar; 136(5):1171-80. PubMed ID: 25043476
[TBL] [Abstract][Full Text] [Related]
18. Human Papillomavirus Genotyping to Predict the Risk of Cervical Precancerous Lesions or Cancer in Women with Minor Abnormal Cytology in China.
Lin CQ; Cui JF; Zhang X; Pan QJ; Chen W; Qiao YL
Acta Cytol; 2015; 59(5):405-11. PubMed ID: 26565687
[TBL] [Abstract][Full Text] [Related]
19. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.
Guo M; Khanna A; Wang J; Dawlett MA; Kologinczak TL; Lyons GR; Bassett RL; Sneige N; Gong Y; Bevers TB
Cancer Cytopathol; 2017 Aug; 125(8):644-651. PubMed ID: 28498639
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of human papillomavirus genotypes among African women with normal cervical cytology and neoplasia: a systematic review and meta-analysis.
Ogembo RK; Gona PN; Seymour AJ; Park HS; Bain PA; Maranda L; Ogembo JG
PLoS One; 2015; 10(4):e0122488. PubMed ID: 25875167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]